News
-
SHPA’s best days lie ahead: Simpson
Friday | Dec 2 2022TASMANIAN leadership of the Society of Hospital Pharmacists of Australia (SHPA) will continue with Tom Simpson, elected to succeed Peter Fowler, as the organisation's new National President.
-
Prescribing trials threaten healthcare
Friday | Dec 2 2022STATE Governments are being urged to reconsider planned pharmacist prescribing trials, with the Australian Medical Association (AMA) warning they will create a two-tier health system.
-
Star Pharmacy celebrates winners
Friday | Dec 2 2022THE Star Pharmacy Group recently held their 2022 Centre of Excellence Conference and Awards Night at scenic Adelaide Oval.
-
Bill to limit pharmacists
Friday | Dec 2 2022LEGISLATION banning lobby groups from making donations of more than $3,000 per electoral term, will limit pharmacists' from supporting political causes, Queensland Senator, James McGrath, says.
-
Access Haleon
Friday | Dec 2 2022PHARMACISTS can now access exclusive offers on all of Haleon's key brands, through the PharmXchange platform.
-
Lucas’ new role
Friday | Dec 2 2022UNIVERSITY of Technology Sydney Pharmacy Practice Senior Lecturer, Dr Cherie Lucas, has been named as the newest Associate Editor of the open access journal, Exploratory Research in Clinical and Social Pharmacy (ERCSP).
-
Melton Pharmacy Superstore joins CDC
Friday | Dec 2 2022PHARMACY Alliance Group is continuing to expand its Chemist Discount Centre (CDC) brand, with Melton Pharmacy Superstore joining the network.
-
HIV handbook
Friday | Dec 2 2022THE International Pharmaceutical Federation (FIP) marked World Aids Day (01 Dec) with the launch of its HIV prevention, screening and management: A handbook for pharmacists.
-
Dispensary Corner 02 Dec 22
Friday | Dec 2 2022WITH the festive season fast approaching, researchers from the University of Queensland and Deakin University have uncovered some interesting findings about boozed up revellers.
-
LGP takes step towards OTC CBD
Thursday | Dec 1 2022MEDICINAL cannabis company, Little Green Pharma (LGP), could be the first to deliver a Schedule 3 product to the Australian market, after securing ethics approval for its Phase III SleepWell Study.
